Menu
Search
|

Menu

Close
X

NantKwest Inc NK.OQ (NASDAQ Stock Exchange Global Select Market)

3.11 USD
+0.00 (+0.00%)
As of 9:44 AM EDT
chart
Previous Close 3.11
Open 3.11
Volume 3,113
3m Avg Volume 60,841
Today’s High 3.12
Today’s Low 3.06
52 Week High 8.43
52 Week Low 3.06
Shares Outstanding (mil) 78.09
Market Capitalization (mil) 242.86
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.348
FY17
-0.545
FY16
-1.475
FY15
-4.069
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.18
Price to Sales (TTM)
vs sector
6,227.06
8.57
Price to Book (MRQ)
vs sector
1.23
4.35
Price to Cash Flow (TTM)
vs sector
--
22.78
Total Debt to Equity (MRQ)
vs sector
0.98
17.37
LT Debt to Equity (MRQ)
vs sector
0.83
12.92
Return on Investment (TTM)
vs sector
-19.09
13.17
Return on Equity (TTM)
vs sector
-19.94
15.15

EXECUTIVE LEADERSHIP

Patrick Soon-Shiong
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: $636,000.00
Bonus: --
Barry Simon
President, Chief Administrative Officer, Director, Since 2017
Salary: $443,822.00
Bonus: --
Steven Gorlin
Vice Chairman of the Board, Since 2014
Salary: --
Bonus: --
Sonja Nelson
Chief Financial Officer, Principal Financial Officer, Since 2018
Salary: $167,327.00
Bonus: --
Michael Blaszyk
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3530 John Hopkins Ct
SAN DIEGO   CA   92121-1121

Phone: +1858.6330300

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

SPONSORED STORIES